


BULGARIA WEEKLY REPORT

Indices							
	Last quote	-	5-day change	1 month	1 year		
SOFIX	561.01	0.04%	2.59%	9.94%	41.31%		
BGBX40	111.80	0.15%	2.08%	8.56%	-		
BGTR30	392.03	0.19%	1.86%	10.01%	32.58%		
BGREIT	90.14	0.18%	1.16%	3.37%	7.14%		

Market Trend



Market Capitalization in BGN

Premium Equities Segment 1 915 904 397
Standard Equities Segment 5 975 157 425
Special Purpose Vehicles
Segment 517 722 691
Total 8 408 784 514

SOFIX components

	Last	Weekly		
Stock	Price	Change	Bid	Ask
Advance Terrafund REIT	2.45	0.20%	2.45	2.46
Albena	58.00	1.75%	57.20	58.00
Bulgaria Real Estate Fund REIT	0.54	-3.58%	0.54	0.55
Bulgartabac Holding	100.00	-3.38%	100.01	104.00
Central Cooperative Bank	1.42	2.75%	1.42	1.43
Chimimport	2.07	1.97%	2.07	2.08
M+S Hydraulic	11.20	-0.88%	11.16	11.39
Eurohold Bulgaria	1.04	4.00%	1.04	1.05
First Investment Bank	3.65	16.99%	3.60	3.61
Industrial Holding Bulgaria	1.07	4.93%	1.07	1.09
Monbat	8.25	0.61%	8.20	8.25
Neochim	53.00	1.92%	53.00	53.75
Sopharma	4.20	6.41%	4.21	4.25
Stara Planina Hold	4.09	2.25%	4.00	4.09
Zarneni Hrani Bulgaria	0.57	5.18%	0.56	0.57

Positive market bias despite high multiples

The notable gainer of the last week was First Investment Bank (5F4) with 17% increase. Investors are very positive toward the bank and it managed to outperform not only the market, which is not very difficult as few stocks are not moving at all, but also Chimimport (6C4). The bank is the favorite stock of the market. The price of the tender offer was announced and as expected it is substantially lower than the latest quotes. Majority owners recently issued a tender offer to minority shareholders in respond to requirements in the law after the changes in ownerships. They transferred stakes from offshore companies that are aiming in more transparency in the ownership of the bank. The difference of tender offer price to latest quotes is due to the solid price increase last month. However, the delisting is not planned and minority shareholders will not sell.

The leader by turnover was pharmaceutical company Sopharma (**3JR**). The pension funds were selling. Bulgarian rose-Sevtopolis (**4BJ**) also jumped. Its performance matched the gains of Sopharma. The company should merge with Sopharma. According to media reports, the buyer of blocks was Rompharm. The company is producing medicines in its facilities in Romania and is exporting to Russia. It became very large buyer of agricultural land in Bulgaria. Its entry in Sopharma could be related to joint operations. Sopharma Trading (**SO5**) also gained with block deals.

Chimimport began to move higher at the end of the week. The last two weeks it was lagging behind leaders and especially FIB. The daily turnover is very good but the phase of distribution is at levels that are 10% lower than the recent highs. The price action looks like a healthy correction and many investors are buying due to the positive market bias. What is unknown is the price action during more broad-based correction in the market.

The price action with leading positions is already raising the question of overextended rally and possible period of correction/consolidation. This is the case of FIB and Sopharma as both stocks are traded at high P/E ratios. The positive trend could continue for several weeks and Chimimport will lead the market if the profit taking diminish.



BULGARIA WEEKLY REPORT

10 February 2014

Disclaimer

Analyst Certification: The research analyst(s) certifies that: (1) all of the views expressed in this document accurately reflect his or her personal views about any and all of the subject securities or issuers; (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this document.

Financial Interest: ELANA Trading may trade or own shares of the analyzed companies. The research analyst(s) is not holding shares of the analyzed companies, unless otherwise noted.

Regulatory Authority: Financial Supervisory Commission, Shar Planina Street 33, 1303 Sofia, Bulgaria

Information Disclosure: All reasonable care has been taken to ensure the facts stated are accurate and opinions given are fair and reasonable. Our recommendations are based on information available to the public that we consider to be reliable but for the completeness and accuracy of which we assume no liability. Neither ELANA Trading, nor its directors, officers or employees shall in any way be responsible for its contents. The views expressed may differ from the views of other firm departments or representatives. Additional information is available upon request. Unless otherwise noted, sources for all information in charts and tables are ELANA Trading's calculations.

Risks for Investors: Information in this document should not be regarded as an offer to buy or sell any financial instruments. The investment possibilities discussed in this document may not be suitable for certain investors depending on their specific investment objectives and time horizon or in the context of their overall financial situation. In particular, the risks associated with an investment in the securities or the financial instruments under discussion are not explained in its entirety.

The prices or values of the securities may go down as well as up and can fluctuate and fall against the investor. The securities or investments may cause the investor to lose the amount invested. Past performance is not a guide to future performance. Changes in exchange rates may have an adverse effect on the value, price or income of the securities or investments.

Valuation Methods: Company valuations are based on the following methods: multiple-based (P/E, P/B, EV/EBITDA), historical valuation approaches, peer comparisons, discount models (DCF, DDM) or asset-based evaluation methods. Valuation models are dependent on macroeconomic factors, including interest rates, foreign exchange rates, prices of raw materials, and any expectations about the economy, the market sentiment. The valuation is based on expectations that might change rapidly and without notice, depending on developments specific to individual industries and countries. Recommendations and target prices derived from the models might therefore change accordingly. The application of models depends on forecasts of a range of economic variables, thus there is a range of reasonable variations within models. Any valuation is dependent upon inputs that are based on the subjective opinion of the analysts carrying out this valuation.

Recommendations: Analyst(s) recommendations are based on the specific factors for the company, sector, country and global developments, as compared to market indices. Recommendations and opinions reflect ELANA Trading's expectations over the 12-month period following publication from the perspective of long-only investment clients. ELANA Trading reserves the right to express different or contrary recommendations and opinions for different timescales or for other types of investment client. Except as otherwise noted, expected performance over next 12 months vary for different recommendations for Bulgarian stocks as follows:

BUY	More than 5% higher as compared to SOFIX and BG40 performance
HOLD	Market performance, +/-5% as compared to SOFIX and BG40
SELL	More than 5% lower as compared to SOFIX and BG40 performance

Frequency of Recommendations: No schedule of recommendations is available. The frequency of recommendations depends on specific factors to individual companies and the opinion of the analyst(s) for the necessity of minor or major changes.

Copyrights: The copyrights of ELANA Trading analyses belong to the Research Department of the brokerage and their content cannot be used for commercial purposes. Replication and redistribution of ELANA Trading analyses content is expressly prohibited without the prior written consent of the appointed contacts listed below.

For more information, please contact:

Research analyst Phone: E-mail: Internet:
Tsvetoslav Tsachev +359 2 810 00 23 tsachev@elana.net www.elana.net